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PREPARATIONS of murine recombinant interferon
(Mu-rIFN)-alpha, -beta and -gamma were assessed for
their influence on in vitro growth of mast cells from
normal mouse spleen cells (Sp C). Mast cell growth was
inhibited by Mu-rIFNs when Sp C were exposed through-
out the entire culture period to Mu-rIFNs. The most potent
inhibitor of mast cell growth was Mu-rIFN-),, followed by
Mu-rIFN-j; Mu-rlFN- had little effect. When added to
IC-2 cells, clonal mast cell progenitor, both Mu-rlFN-]
and -), significantly inhibited proliferative response of the
target cells. The suppressive effect of Mu-rIFNs on IC-2
cells was selectively abolished by monoclonal antibodies
against iu-rIFN-/ and y.
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Introduction
Interferons (IFNs) are well known to be a family
of inducible proteins secreted by several types of
cells in response to viruses and other stimuli. It is
also generally accepted that IFNs can be divided
into three different subclasses, IFN-z,-fl and-
based on their structure, cellular origin and
biological properties.
The effect of IFNs on cell proliferation was
examined extensively by many investigators and
IFN-z and- have been shown to suppress the in
vitro proliferation and/or differentiation of human
pulripotent hemopoietic progenitor cells and of
committed progenitor cells. 1-3 Recently, Nafzigar et
al.,
4 using normal mouse bone marrow cells,
examined the effect of IFN-y on mast cell growth
and reported that IFN-), strongly inhibited their
growth when bone marrow cells were exposed
throughout the entire culture period to IFN-2
which seemed to exert its inhibitory activity on mast
cell progenitors. There is, however, no evidence for
a direct effect of IFN-2 on mast cell progenitors.
Furthermore, no information is yet available
concerning the effects of IFN-z and -]5 on mast cell
growth and proliferation.
The aim of the present study, therefore, is to
evaluate the in vitro effects of IFN-0 and-15 on mast
cells. In addition, studies were performed to
investigate whether an inhibitory activity of IFN-2
on mast cell growth was due to a direct effect on
progenitor ceils.
(C) 1993 Rapid Communications of Oxford Ltd
Materials and Methods
Mice: Male BALB/c mice, 7 weeks old, were
purchased from Charles River Japan Inc., Atsugi,
Japan.
Cell line: Clonal mast cell progenitor IC-2 cell line
was kindly supplied by Cell Bank, Riken Gene
Bank, Ibaragi, Japan.
IFN and monoclonal antibody to IFN: Murine-re-
combinant IFN (Mu-rlFN)-cz (Spe. Act. 1.1 x 106
U/ml) and-fl (specific activity 1.1 x 106 U/ml) were
purchased from Lee Biomolecular Research Lab.,
Inc., San Diego, CA. Mu-rIFN-y (specific activity
1.9 x 106 U/ml) was kindly provided by Toray
(Kanagawa, Japan). To neutralize the activity of
Mu-rIFNs, 25g of monoclonal antibodies to
Mu-rIFN-fl (Lee Biomolecular Research Lab. Inc.)
and to Mu-rIFN-y (Genzyme Corp., Cambridge,
MA) were incubated with 100 #1 of the appropriate
Mu-rlFN preparations for 90min at 37C just
before use.
Induction of mast cellsfrom normal mouse spleen cells: Spleen
cell suspension (Sp C) was prepared as described
previously.
6 The cells were adjusted to 5 x 106
cells/ml or 10 x 106 cells/ml in RPMI-1640 medium
(Flow Lab., Irvine, Scotland) supplemented with
10% foetal calf serum (Bocknek, Canada), 25 mM
HEPES, 200 mM L-glutamine, 100 U/ml penicillin
100 g/ml streptomycin, and 30% interleukin 3
culture supplement (Collaborative Biomedical pro-
ducts, Bedford, MA). The cells (1 ml/well) were
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incubated in 24-well culture plates (Nunc, In-
termed, Denmark) at 37C in a humidified
atmosphere with 5% COg.
IFN treatment: Mu-rIFNs were added to cultured
cells at seeding and then every 4 days, when the
culture medium was replaced with fresh medium.
To study the effects of Mu-rlFNs at different stages
of mast cell growth, another series of experiments
was carried out, in which Mu-rIFNs were added at
seeding or 10 days after seeding.
Cell counts: Every 4 days, the growth of cells was
measured by counting cells with a hemocytometer.
Cell viability was determined by trypan blue
exclusion. Mast cells were counted by a staining
method with alcian blue specific for counting
basophils and mast cells, v
Cell proliferation: IC-2 cells at a concentration of
2 x 105 cells/ml were introduced into each well of
96-well flat-bottomed culture plates (Nunc, In-
termed) that contained Mu-rIFNs in a final volume
of 0.2 ml. The plate was maintained at 37C in a
humidified atmosphere with 5% COg. After 40 h,
1.0 #Ci of3H-thymidine (specific activity 25 Ci/mM,
Amersham International Plc, Buckinghamshire,
UK) was added and the plate was maintained for a
further 8 h. Cell proliferation was assessed by
determination of the rate of incorporation of
3H-thymidine into DNA as described previously.
6
Statistical analysis" Data from control and experi-
mental groups were compared by Student’s t-test.
Results
Influence of IFNs on mast cell growth" To examine
effects of Mu-rIFNs on mast cell induction,
10 x 106 Sp C were cultured in the presence of
either IFN-,-/3 or- (100 U/ml each), and the
numbers of viable cells and mast cells were
counted. As the culture time went on, viable cell
numbers decreased gradually in the culture (Fig.
1A). When Sp C were cultured without Mu-rIFNs
(Control), the mast cell numbers were gradually
increased, peaked on the sixteenth day (Fig. 1B).
In contrast to the results obtained in cultures
exposed to Mu-rIFN-0q a statistically significant
suppression of mast cell growth was observed when
Sp C were exposed throughout the entire culture
period to Mu-rIFN-fl and -y (Fig. 1B).
The second experiments were carried out to
examine whether mast cell growth inhibition by
Mu-rlFN-/3 and -y was associated with concentra-
tion of Mu-rIFNs added to cultures. To accomplish
this, 5 x 106 Sp C were cultured in the presence of
four different doses of Mu-rIFNs and the number
of mast cells was counted. As shown in Fig. 2,
dose-dependent suppression was observed: 50 and
100 U/ml of Mu-rIFN-/3 failed to suppress mast cell
growth but 500 and 1000 U/ml strongly suppressed
them. The data in Fig. 2 also indicated that the
suppression exerted by Mu-rIFN-y was stronger
than that by Mu-rIFN-fl.
The third experiments were designed to
examine the effects of Mu-rIFNs in different
stages of mast cells. As shown in Fig. 3, addition
of Mu-rIFN-fl and-y (1000 U/rnl each) at seeding
of 5 x 106 Sp C significantly inhibited mast cell
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FIG. 1. Influence of interferons on viable cells and mast cell induction in cultured murine splenocytes. Mu-rlFNs (1000 U/ml) were added at the
time of seeding spleen cells (10 x 106 cells/ml) and then every 4 days, when the culture medium was replaced with the fresh medium. Results are
expressed as the mean -I- S.E. of two different experiments.
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FIG. 2. Effects of murine-recombinant interferons (Mu-rlFNs) on mast
cell growth. Mu-rlFNs were added at the time of seeding spleen cells
(5 106 cells/ml) and then every 4 days, when the culture medium was
replaced with a fresh medium. Mast cell growth was evaluated 16 days
after culture. Results are expressed as the mean _+ S.E. of two different
experiments. Asterisks indicate p < 0.05 versus control (None).
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FIG. 3. Effects of adding murine-recombinant interferons (Mu-rlFNs) at
different times after seeding spleen cells. Mu-rlFNs were added to the
culture medium on days 0 and 10, and mast cell growth was evaluated on
day 16. The values are the mean _+ S.E. of two different experiments.
Asterisks indicate p < 0.05 versus control.
growth. However, no such inhibition was observed
when Mu-rIFNs were added to the cells after 10
days of culture.
In)quence of Mu-rlFNs on mast cell progenitors: The final
experiments were carried out to examine whether
Mu-rlFN-fl and- exerted their inhibitory effects
described above by acting directly on mast cell
precursors. For this purpose, IC-2 cells, mast cell
progenitors were cultured in the presence of
Mu-rlFNs and cell proliferation was examined. As
shown in Table 1, addition of Mu-rIFN-fl and -7
significantly inhibited IC-2 cell proliferation in dose
Table 1. Effect of interferons (IFN) on the proliferation of IC-2
cell line
Dose of FN
(Ulml)
Proliferation (cpm -t- S.E.)
IFN-fl IFN-7
None 272 452.0 _+ 4401.5 252 742.0 _+ 10430.1
(control)
50 262 153.7 + 21 504.1 254 093.3 + 2 218.7
100 221 744.0 _+ 7 053.4 112 901.7 _+ 17 508.0*
500 206 167.1 + 9 350.1 * 92 088.1 + 4 032.5*
1000 130 673.4 + 38 264.0* 47 678.3 + 3 504.4*
Clonal mast cell precursors, IC-2 cells, at a concentration of
2 105 cells/ml were cultured with 3H-thymidine in a culture
plate containing Mu-rlFNs. Asterisks indicate p < 0.05 versus
control.
Table 2. Specific inactivation of the suppressive influence of
murine-recombinant interferons (Mu-rlFNs)-fl and -7 on IC-2
cell proliferation by pre-incubation of the interferons with their
respective antibodies
3H-thymidine uptake
(cpm +_ S.E.)
Control (medium alone)
Mu-rlFN-fl (103 U/ml)
Mu-rlFN-fl + anti-IFN-beta
Mu-rlFN-? (103 U/ml)
Mu-rlFN- + anti-IFN-gamma
276 728.3 _+ 8 228.7
76 454.3 + 6 544.4*
279 116.3 +_ 4 370.3
41 995.0 + 3 011.1
214557.3 + 7 428.1
Preparations of Mu-rlFNs were preincubated for 90 min at 37C
with or without 104 neutralizing units of monoclonal antibodies
to Mu-rlFN-fl or Mu-rlFN-y. Asterisks indicate p < 0.05 versus
control.
dependent manner. These inhibitory actions were
completely abolished when Mu-rIFNs were pre-
incubated with monoclonal antibodies suitable to
the appropriate IFN type (Table 2).
Discussion
The results of this study demonstrated that: (1)
both rIFN-fl and -, but not-, are potent
inhibitors of murine mast cell proliferation; (2)
rIFN-/ and-2 exert their inhibitory activity on mast
cell progenitors, but not on mature mast cells.
These conclusions are supported by the following
observations: firstly, when Sp C were exposed
throughout the entire culture period to rIFN-/ and
-, a statistically significant and dose-dependent
suppression of mast cell growth was observed,
whereas no such inhibition was observed when
Mu-rIFN-0 was added to the cultures at seeding of
Sp C. Secondly, addition of rIFN-/ and- to the
culture medium at seeding strongly inhibited mast
cell growth. However, addition of rIFNs 10 days
after seeding, when differentiation of precursors and
proliferation of immature mast cells are progressed,
did not affect mast cell growth, as assessed by
mast cell number observed on day 16. Finally,
proliferation of IC-2 cells, clonal mast cell
progenitors, was strongly inhibited when the cells
were cultured in vitro with rIFN-/ and -7. This
inhibition was completely neutralized when the
IFNs were pre-incubated with a monoclonal
antibody directed to the appropriate IFN type.
As far as we know, the present experiments are
the first to demonstrate that IFN-7 exerts its
antiproliferative effect on mast cells by acting
directly on their precursors and to show that IFN-fl,
but not IFN- has biological effects on mast cells
similar to those of IFN-y.
IFN-fl could exert its anti-proliferative effect by
acting directly on mast cell precursors and various
mechanisms can be envisaged. IFN-fl might act on
Ia antigen and result in inhibition of mast cell
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growth. Indeed, under certain conditions, Ia
antigen was shown to be involved in the negative
regulation of cell growth. 8’9 Alternatively, down-
regulation of oncogene expression, demonstrated
by the addition of IFNs to in vitro experimental
models,
1 might also explain the anti-proliferative
activity of IFN-fl on mast cells. The possibility that
other cells present in early cultures could be
involved in the mediation of inhibitory effect of
IFN-fl cannot be excluded, since a role of accessory
cells such as lymphocytes and monocytes was
reported in the suppression of normal erythropoi-
esis by IFN-y.
11 It is well known that IFNs exert
their pleiotropic effects by interacting with specific
receptors on the surface membrane. Nafzigar et al.4
reported that IFN-y inhibits in vitro mast cell growth
by formation of IFN-2-receptor complex, suggest-
ing that IFN-fl binds to specific receptor for IFN-fl
differed from that for IFN-
12’13 on mast cell
precursors and result in inhibition of mast cell
growth. Anyway, further experimentations are
needed to clarify the precise mechanisms by which
IFN-fl inhibits mast cell growth.
IFNs have been employed successfully in the
14 treatment of some infectious diseases and cancers.
So far, no clinical applications have been made of
their potent immunoregulatory effects, although the
inhibitory effect of IFNs on the mycotic disease
induced by A spergilus fumigatus
15 and on leproma-
tous leprosy
16 may depend on the activation of
macrophages and T-cells, respectively. Mast cells
are now considered to play a pivotal role not only
in allergic reactions but also in many pathological
immune responses, lv’18 It is also well known that
infiltration of mast cells and the presence of mast
cell-derived soluble mediators in the presence of
asthma and atopic allergy are well correlated with
the severity of the diseases. From these reports,
whatever the mechanisms involved, our in vitro
results suggest that IFN-fl and-y could act in vivo
as inhibitory factors of mast cell proliferation and
that these lymphokines could be of interest in the
treatment of asthma and atopic allergy.
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